JOHN TILMON: Open Payments
NPI 1619903721 · STERLINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$968 in 41 payments from 15 companies in 2025. Trend: 2023 $453 · 2024 $663 · 2025 $968
Food & beverage: $912Education: $56
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $253 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $155 |
| Ardelyx, Inc. | 1 | $114 |
| Otsuka America Pharmaceutical, Inc. | 3 | $86 |
| Novo Nordisk Inc | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Neurocrine BioSciences, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $33 |
| Abbott Laboratories | 2 | $30 |
Products named: Kerendia, IBSRELA, QULIPTA, UBRELVY, REXULTI, VRAYLAR, AUSTEDO XR, INGREZZA.
Industry payments across LA — which companies pay providers there.
